Progressive, largely irreversible airflow limitation from chronic bronchitis and/or emphysema.
Also known as: COPD, emphysema, chronic bronchitis, AECOPD, chronic obstructive lung disease
Overview
Heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum, exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive airflow obstruction (post-bronchodilator FEV1/FVC <0.7).
Epidemiology
Third leading cause of death worldwide. ~16 million diagnosed in the US; many more undiagnosed. Smoking accounts for ~80% of cases in high-income countries; biomass fuel exposure dominates in low-income settings.
Try two board-style Chronic Obstructive Pulmonary Disease questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1PulmonaryMedium
A 45-year-old man with chronic obstructive pulmonary disease (COPD) reports two exacerbations in the past year, one of which required an emergency visit. He uses a short-acting bronchodilator only as needed but remains symptomatic with exertional dyspnea, and he continues to smoke. Post-bronchodilator spirometry shows an FEV1 of 55% predicted, and the blood eosinophil count is 120 cells/uL. Which of the following inhaler regimens is the most appropriate initial maintenance therapy?
ALAMA + LABA + ICS
BLAMA monotherapy
CICS monotherapy
DLAMA + LABA
Reveal answer & full explanation
Correct answer: D — LAMA + LABA
ALAMA + LABA + ICS
BLAMA monotherapy
CICS monotherapy
DLAMA + LABA✓
Why LAMA + LABA is correct
This patient meets GOLD Group E criteria (two exacerbations in the past year, including one requiring an emergency visit), which defines high future-exacerbation risk
Per current GOLD guidance, the preferred initial maintenance therapy for Group E is dual long-acting bronchodilation with a long-acting muscarinic antagonist (LAMA) plus a long-acting beta-agonist (LABA)
A blood eosinophil count below 300 cells/uL argues against starting an inhaled corticosteroid (ICS), which is added mainly when eosinophils are 300 cells/uL or higher or when exacerbations persist on dual bronchodilators
Why the others are wrong
LAMA + LABA + ICS — triple therapy is an escalation step (or initial therapy only when eosinophils are at least 300 cells/uL); with eosinophils of 120 cells/uL it is not the appropriate starting regimen (right-diagnosis-wrong-step)
LAMA monotherapy — a single long-acting bronchodilator is maintenance therapy, but GOLD favors dual LAMA plus LABA over either agent by itself in Group E because the combination produces greater symptom relief and fewer exacerbations (right-category-wrong-intensity)
ICS monotherapy — an inhaled corticosteroid without a bronchodilator backbone is not recommended at any stage of COPD and increases pneumonia risk (confused with first-line asthma management)
Question 2PulmonaryMedium
A 55-year-old man with chronic obstructive pulmonary disease (COPD) is admitted with an acute exacerbation. SpO2 is 88% on room air. Which of the following is the most appropriate oxygen saturation target?
ASpO2 98-100%
BSpO2 94-98%
CSpO2 88-92%
DSpO2 84-87%
Reveal answer & full explanation
Correct answer: C — SpO2 88-92%
ASpO2 98-100%
BSpO2 94-98%
CSpO2 88-92%✓
DSpO2 84-87%
Why SpO2 88-92% is correct
In acute exacerbations of chronic obstructive pulmonary disease (COPD), the target SpO2 is 88-92%.
Higher saturations risk worsening hypercapnia via the Haldane effect and ventilation/perfusion (V/Q) mismatch.
Why the others are wrong
SpO2 98-100% — over-oxygenation in COPD risks CO2 retention and respiratory acidosis via the Haldane effect and V/Q mismatch
SpO2 94-98% — an appropriate target for most acutely ill patients without CO2-retention risk, but too high for a COPD patient prone to hypercapnia
SpO2 84-87% — unnecessarily low and risks tissue hypoxia; the goal is 88-92%, not deliberate hypoxemia
Additional high-yield points
Use controlled low-flow oxygen (Venturi mask preferred).
Initiate bilevel positive airway pressure (BiPAP) if pH falls below 7.35 after initial therapy.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Chronic Obstructive Pulmonary Disease (COPD) outline — plus all 514 diagnoses, 6,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Idiopathic pulmonary fibrosis — Restrictive pattern on PFTs, dry cough, bibasilar Velcro crackles, honeycombing on HRCT
Alpha-1 antitrypsin deficiency — Premature emphysema (<45 years), basal-predominant on CT, family history; serum AAT level <11 µM
Constrictive (obliterative) bronchiolitis — Post-transplant, post-viral, or connective tissue disease; mosaic attenuation on expiratory CT
Diagnostic workup
Diagnostic criteria
GOLD 2024: symptoms + risk factor exposure + post-bronchodilator FEV1/FVC <0.7. Severity by FEV1 % predicted; clinical group (E, A, B) by symptoms (mMRC, CAT) and exacerbation history.
Labs
Alpha-1 antitrypsin level (once per lifetime, all COPD patients per GOLD)
ABG if severe disease or exacerbation (hypoxia, hypercapnia)
CBC (polycythemia from chronic hypoxia; eosinophilia ≥300 informs ICS use)
flowchart TD
A[Suspect COPD<br/>dyspnea, cough, risk factors] --> B[Post-bronchodilator<br/>spirometry]
B --> C{FEV1/FVC<br/>< 0.7?}
C -->|No| D[Consider alternative<br/>diagnosis]
C -->|Yes| E[COPD confirmed]
E --> F[Assess symptoms<br/>mMRC, CAT]
E --> G[Assess exacerbations<br/>past 12 months]
F --> H{GOLD Group}
G --> H
H -->|Group A| I[SABA/SAMA<br/>or single LA bronchodilator]
H -->|Group B| J[LABA + LAMA]
H -->|Group E| K[LABA + LAMA<br/>+ ICS if eos ≥300]
GOLD 2024 diagnosis and initial pharmacologic treatment algorithm.
Treatment
First-line
Smoking cessation — single most important intervention; reduces rate of FEV1 decline
Pulmonary rehabilitation for mMRC ≥2 or after exacerbation
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.